Enzyme therapy in Fabry disease: severe adverse events associated with anti‐agalsidase cross‐reactive IgG antibodies

Abstract

The negativity of immunological tests (specific anti-agalsidase IgE antibodies and skin tests) does not rule out the risk of repeated anaphylactoid shock following agalsidase infusion.